-
Mashup Score: 34Bladder Cancer Highlights From ESMO 2023: Comparing and Contrasting EV302 and CheckMate 901 - 6 month(s) ago
Bladder Cancer Highlights From ESMO 2023: Comparing and Contrasting EV302 and CheckMate 901
Source: www.vumedi.comCategories: General Medicine News, UrologyTweet
Bladder Cancer Highlights From #ESMO23: Honored to compare and contrast the design and results of the landmark EV302 and CheckMate901 Phase III trials in the first-line setting of advanced #urothelialcarcinoma #bladdercancer @BladderCancerUS | VuMedi https://t.co/dyBJZ7heH4 via… https://t.co/suKK0VD66l